Home › Smart-ABI Alternatives › Smart-ABI vs. Traditional Clinical Assessment
ComparisonSmart-ABI vs. Traditional Clinical Assessment: Why Early PAD Detection Changes Everything
The patient most likely to have peripheral artery disease looks fine. They answer the screening questions, pass the foot exam, and leave with every documented condition managed. Nothing in the visit points to vascular disease. That is exactly the problem.
An estimated two out of three patients with PAD or peripheral neuropathy are asymptomatic. Intermittent claudication, the classic symptom clinicians are trained to watch for, appears in only a small percentage of affected patients. By the time symptoms make the diagnosis obvious, the window for early intervention has often already closed.
That leaves every practice facing an uncomfortable question: if the disease is usually silent, how much can you trust an assessment built on symptoms, pulse palpation, and clinical impression?
The pressure comes from more than the disease itself. Value-based care, documentation scrutiny, and chronic disease management all demand objective data that traditional clinical assessment was never designed to produce. The question is no longer whether a patient eventually gets a diagnosis. It is whether the diagnosis arrives early enough to change the outcome, with the documentation to back it up.
That is the comparison this article makes. Not one device against another, but two approaches to vascular assessment: the traditional exam-and-refer pathway, and quantitative testing built into the routine office visit.
What Is the Ankle-Brachial Index (ABI) and Why Does It Matter?
The Ankle-Brachial Index (ABI) is one of the most established noninvasive methods for identifying Peripheral Artery Disease. Although the calculation itself is straightforward, its clinical value extends far beyond a simple ratio.
An ABI compares the systolic blood pressure measured at the ankle with the systolic blood pressure measured in the arm. Under normal circumstances, pressure at the ankle should be equal to or slightly higher than pressure in the brachial artery. When the ratio falls below normal thresholds, it may indicate narrowing or blockage of the lower-extremity arteries caused by atherosclerosis. According to the evidence review prepared for the U.S. Preventive Services Task Force, ABI values of 1.00 to 1.30 are considered normal, values of 0.41 to 0.90 indicate mild to moderate PAD, and values of 0.40 or below indicate severe PAD.
The procedure itself is uncomplicated. After a brief period of rest, blood pressure cuffs are placed on both arms and both ankles. Measurements are obtained from the dorsalis pedis and posterior tibial arteries, allowing the clinician to calculate an objective ABI value for each leg.
Unlike imaging studies that require specialized facilities or expose patients to radiation, ABI testing is painless, noninvasive, and can typically be completed in just a few minutes.
Multiple studies have demonstrated that ABI has excellent diagnostic performance for detecting significant lower-extremity arterial disease when compared with angiography, often reporting sensitivity above 90 percent and specificity above 95 percent, figures reflected in the American Heart Association's scientific statement on ABI measurement and interpretation. Beyond diagnosing PAD itself, an abnormal ABI is also recognized as an independent predictor of myocardial infarction, stroke, and cardiovascular mortality, making it an important marker of overall cardiovascular risk rather than simply a measure of circulation in the legs.
Clinical guidelines reflect this importance. The American Heart Association (AHA) and American College of Cardiology (ACC) recommend ABI evaluation for adults aged 65 years and older, adults over 50 with diabetes or a history of smoking, and individuals of any age presenting with exertional leg symptoms or non-healing wounds. Rather than encouraging indiscriminate screening, these recommendations focus on identifying high-risk populations where earlier detection is most likely to improve clinical decision-making.
For practices serving patients with diabetes, cardiovascular disease, chronic wounds, or multiple vascular risk factors, ABI testing represents far more than another diagnostic procedure. It provides objective information that can influence treatment decisions while helping clinicians better understand a patient's overall cardiovascular health.
The Limitations of Traditional Clinical Assessment
To appreciate what Smart-ABI offers, it is first necessary to understand what “traditional clinical assessment” actually means in everyday clinical practice.
Traditional clinical assessment does not imply poor medicine or inadequate care. It simply describes the familiar exam-and-refer workflow used by many practices that do not perform ABI testing in-house.
In this model, clinicians evaluate patients through medical history, physical examination, pulse palpation, and, when neuropathy is suspected, conventional neurological assessments such as monofilament testing, vibration perception, and reflex evaluation. If concerns arise during those assessments, patients may then be referred to another facility for vascular testing.
There are understandable reasons why this approach remains common. It requires no additional equipment. Clinical staff already know the workflow. Practices avoid the upfront investment associated with diagnostic technology.
For patients whose disease has progressed enough to produce obvious symptoms, the system often works as intended. Individuals experiencing severe claudication, rest pain, non-healing ulcers, or absent peripheral pulses are more likely to receive additional evaluation.
The challenge is that many patients never reach that point before opportunities for earlier intervention are missed. When objective vascular testing is unavailable, practices rely primarily on symptoms and clinical examination to determine who should undergo additional evaluation. For a condition that is frequently asymptomatic in its earlier stages, that approach may delay diagnosis in patients who could benefit from earlier assessment.
What Is Smart-ABI?
Smart-ABI was developed to address a challenge that traditional workflows were never designed to solve: bringing objective vascular assessment directly into routine clinical practice without adding unnecessary complexity.
Instead of requiring patients to schedule additional appointments elsewhere, Smart-ABI enables practices to perform quantitative ABI and Volume Plethysmography Records (VPR) testing during the office visit itself. The system is designed around simplicity.
A medical assistant, not necessarily the physician, can complete the study using guided workflows that standardize the testing process from start to finish. Within approximately five minutes, the practice receives a quantitative, color-coded report that can be incorporated directly into the patient's electronic medical record (EMR).
For practices seeking broader neurological assessment, the Smart-LEDA+ platform expands testing beyond vascular disease by incorporating sudomotor evaluation to assess autonomic and small-fiber nerve function. This additional capability provides another layer of objective information that physical examinations alone cannot provide.
Importantly, Smart-ABI is not intended to replace clinical judgment. It complements it.
Why Smart-ABI?
The clinical value of ABI testing is well established. The next question is how practices choose to incorporate it into everyday care. The comparison below examines five questions every practice should consider when evaluating their current vascular and neuropathy assessment workflow.
Detection Reach
Does it identify disease before symptoms appear or only confirm what is already clinically apparent?
The most significant difference between Smart-ABI and traditional clinical assessment is not convenience. It is visibility.
A traditional assessment pathway largely identifies disease after patients develop symptoms significant enough to prompt further investigation. Smart-ABI is designed to detect disease before those symptoms become the primary reason for testing.
That distinction matters because the majority of patients with Peripheral Artery Disease do not initially present with the classic symptoms clinicians are taught to recognize.
By producing a quantitative ABI value alongside Volume Plethysmography Records (VPR) waveforms, Smart-ABI provides objective evidence of arterial disease even when physical examination appears relatively unremarkable.
Instead of asking whether disease is obvious, the technology asks whether disease is already measurable. For practices managing high-risk patient populations, that difference has meaningful clinical implications by supporting earlier clinical evaluation before disease progresses to more advanced stages.
Diagnostic Confidence
Does it produce objective, reproducible measurements or rely primarily on clinical judgment?
Clinical experience remains one of medicine's greatest assets. However, experience and objective measurement serve different purposes.
Pulse palpation, symptom assessment, and physical examination provide valuable clinical impressions, but they cannot generate standardized numerical values that can be compared across visits or incorporated into longitudinal disease management.
ABI testing changes that. Because Smart-ABI produces reproducible quantitative measurements supported by established clinical evidence, clinicians gain objective data that can strengthen diagnostic confidence while creating consistent baselines for future comparison.
Instead of documenting that peripheral pulses appeared diminished, providers can document measurable vascular findings supported by standardized testing. That difference extends beyond diagnosis itself, providing objective information that supports clinical decision-making over time.
Neuropathy Assessment
Can it detect early nerve dysfunction before conventional foot examinations reveal significant damage?
Peripheral artery disease is only one piece of the clinical picture. For many practices, particularly those caring for patients with diabetes, identifying peripheral neuropathy early is equally important.
The challenge is that conventional neurological examinations are designed to detect damage that has already progressed. Monofilament testing, vibration perception, and tendon reflexes primarily assess large-fiber nerve function and identify loss of protective sensation. While these assessments remain valuable components of diabetic foot care, they offer limited visibility into the earliest stages of nerve dysfunction.
Small-fiber and autonomic neuropathy often develop much sooner. These smaller nerve fibers regulate sweat gland activity, skin integrity, and other autonomic functions that may deteriorate well before patients report numbness, pain, or balance problems. By the time abnormalities appear during a routine foot examination, nerve damage may already be well established.
This is where the Smart-LEDA+ platform extends beyond traditional ABI testing.
By incorporating sudomotor testing, Smart-LEDA+ evaluates autonomic and small-fiber nerve function through objective physiological measurements rather than relying solely on physical examination. The result is additional clinical information that may help providers recognize neuropathic changes earlier in appropriate high-risk patients.
Documentation
Does it generate the objective evidence needed to support today's documentation and reimbursement requirements?
Clinical care does not end with making the correct diagnosis. It also requires documenting that diagnosis in a manner that supports reimbursement, continuity of care, and regulatory compliance.
Historically, many practices relied on narrative documentation describing diminished pulses, absent symptoms, or qualitative clinical impressions. While those notes reflected the physician's judgment, they often lacked the objective evidence increasingly expected in today's reimbursement environment.
Healthcare documentation has become considerably more demanding. As claims review processes continue to evolve, including greater use of automated and AI-assisted review systems, providers face growing expectations for objective, well-supported clinical documentation. Inadequate documentation may increase the likelihood of claim denials, additional review, or reimbursement challenges.
Smart-ABI addresses this need by generating standardized, quantitative reports that include ABI values, Volume Plethysmography Records (VPR) waveforms, and color-coded findings that can be incorporated directly into the patient's electronic medical record.
Instead of relying exclusively on descriptive chart notes, practices can document measurable vascular findings supported by reproducible testing.
That distinction becomes particularly valuable when patients require ongoing monitoring, specialist referrals, chronic disease management, or reimbursement for vascular assessment performed in the office. For wound care practices, objective ABI documentation may also support reimbursement where vascular assessment is necessary to substantiate treatment decisions and certain wound-related claims.
Objective documentation strengthens not only the medical record but also the consistency and defensibility of clinical decision-making.
Workflow and Reimbursement
Does the practice capture the full clinical and financial value of the care it provides?
One of the biggest concerns about introducing in-office ABI testing is whether it will add another burden to an already busy practice. Physicians are managing increasing patient volumes, documentation requirements, and administrative responsibilities, so any new technology must fit naturally into the existing workflow.
Smart-ABI was designed with that reality in mind. The guided workflow enables trained medical assistants to perform the study from data entry through report generation, allowing physicians to review the results rather than conduct every step themselves. In approximately five minutes, the practice receives a standardized, color-coded report that can be reviewed alongside the patient's clinical information.
Performing testing in-house also improves the patient experience. Instead of referring patients to another facility, scheduling additional appointments, and waiting days for results, practices can complete the vascular assessment during the same visit. This reduces delays, minimizes referral leakage, improves continuity of care, and helps ensure that appropriate diagnostic evaluations are completed rather than deferred or missed altogether.
The operational benefits extend beyond efficiency. Practices that refer patients elsewhere retain the evaluation and management visit but transfer the reimbursable vascular study to another provider. By performing eligible noninvasive vascular studies in-house, practices may bill the appropriate CPT codes, including 93922 or 93923, while Smart-LEDA+ may also support reimbursement under CPT 95923 when clinically appropriate.
As healthcare continues to move toward value-based care, objective documentation has become increasingly important. Practices that do not identify PAD or early neuropathy may underrepresent the true disease burden of their patient population, limiting opportunities within risk-adjustment and other value-based care programs. By combining efficient workflow, standardized reporting, and in-office testing, Smart-ABI helps practices strengthen documentation, support appropriate reimbursement, and deliver more coordinated care without disrupting everyday operations.
What to Do Next
Peripheral artery disease is becoming an increasingly significant healthcare challenge, with researchers projecting a substantial rise in cases over the coming decades. As more patients present with diabetes, cardiovascular disease, and other vascular risk factors, practices face an important question: is the current approach to vascular assessment identifying disease early enough to make a meaningful difference?
A practical starting point is to evaluate the current patient population. Consider how many patients are over 65, living with diabetes, have a history of smoking, known cardiovascular disease, or non-healing wounds. Then review how many of those patients are referred elsewhere for ABI testing, how many complete those referrals, and whether objective vascular documentation is consistently available when it is needed.
Ultimately, the comparison between Smart-ABI and traditional clinical assessment is a comparison between two different approaches to care. The traditional pathway responds to disease after clinical suspicion develops, relying on physical examination, referrals, and qualitative documentation. Smart-ABI brings objective vascular testing into the practice, helping clinicians evaluate appropriate high-risk patients earlier, generate standardized documentation, keep testing in-house, and support more informed clinical decision-making.
Ready to see how Smart-ABI fits into your practice? Schedule an on-site or virtual demonstration to learn how in-office ABI testing can be integrated into your existing workflow.